Skip to content Skip to footer
Subscribe Now

Uncategorized

Matchpoint Therapeutics and Novartis
Matchpoint Therapeutics Collaborates with Novartis to Develop Oral Covalent Inhibitors for Various Inflammatory Diseases
Shots: Matchpoint & Novartis have entered into an exclusive option & license agreement to develop & commercialize oral covalent inhibitors targeting a transcription factor in inflammatory diseases using Matchpoint’s ACE platform As per the deal, Matchpoint will lead all research activities through development candidate selection with funding from Novartis. Matchpoint will receive $60M in upfront & funding…
17 hours ago
Disease of the Month – Angina 
Shots:  Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
June 25, 2025
Valorum Biologics and Formycon
Valorum Biologics and Formycon Collaborate to Commercialize FYB203 (Biosimilar, Eylea) Across US and Canada 
Shots:  Formycon has reported that Klinge Biopharma, holder of global rights to FYB203/Ahzantive (aflibercept-mrbb), has signed an exclusive licensing deal with Valorum Biologics for commercialization across the US and Canada  As per the deal, Klinge will receive upfront, milestone, and royalty payments on net sales. Formycon will receive a mid-single—to low-double-digit percentage of all payments…
June 25, 2025
PharmaShots Weekly Snapshots (Jun 02, 2025 – Jun 06, 2025)   
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, COVID-19 & Animal Health. Check out our full report below:    AstraZeneca Presents P-III (MATTERHORN) Trial Data of Imfinzi as Perioperative Therapy for G/GEJ Cancers at ASCO 2025  Read More: AstraZeneca  Novartis Reveals Interim P-III (PSMAddition) Trial Data of Pluvicto…
June 6, 2025
Technology’s Impact on Training Future Healthcare Personnel
The integration of cutting-edge technological tools and methodologies has revolutionized the way healthcare education is delivered, offering both educators and students unparalleled opportunities for growth and learning. This article delves into the profound impact of technology on the training of future healthcare professionals, highlighting the transformative potential it holds for preparing a new generation of…
February 21, 2024